Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

ClinicalTrials.gov ID: NCT01660906

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01660906. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

Study identification

NCT ID: NCT01660906
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 39 participants

Conditions and interventions

Conditions

Chronic Phase Chronic Myeloid Leukemia

Interventions

Dasatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2012 (Type not available)
Primary completion: Oct 2015 (Actual)
Completion: Oct 2015 (Actual)
Last update posted: Nov 22, 2016

2012 – 2015

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Pacific Cancer Medical Center	Anaheim	California	92801	—
Cancer Center Of Central Connecticut	Southington	Connecticut	06489	—
St. Agnes Healthcare, Inc.	Baltimore	Maryland	21229	—
Promedica Hematology & Oncology Assoicates	Sylvania	Ohio	43560	—
The University Of Texas Md Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01660906, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 22, 2016 · Synced Nov 15, 2026